key: cord-0758791-4z0fno86
authors: Gaudino, Mario; Arvind, Varun; Hameed, Irbaz; Di Franco, Antonino; Spadaccio, Cristiano; Bhatt, Deepak L.; Bagiella, Emilia
title: Effects of the COVID-19 Pandemic on Active Non-COVID Clinical Trials
date: 2020-09-29
journal: J Am Coll Cardiol
DOI: 10.1016/j.jacc.2020.07.051
sha: 05ef968c3fa752818089acc276edb076cd19274b
doc_id: 758791
cord_uid: 4z0fno86

nan

Effects of the COVID-19 Pandemic on Active Non-COVID Clinical Trials

The coronavirus disease-2019 (COVID-19) pandemic has created unprecedented challenges in clinical research activities; its effects on ongoing clinical trials has not been yet quantified (1, 2) . In this report, we provide a description of the effect of the COVID-19 pandemic on ongoing clinical trials.

Historical metadata of all trials reported on Clin-icalTrials.gov from January 1, 2017, to May 31, 2020, were queried by using Python (Python Software Foundation, Beaverton, Oregon). The months from January 1 to May 31, 2020, were defined as the COVID-19 pandemic period. Non-COVID-19-related trials were identified by excluding "COVID," "coronavirus," and "SARS-CoV-2" in trial titles. Stopping a trial was defined as a switch in trial status from "recruiting" to "active and not recruiting," "completed," "suspended," "terminated," or "with- We found that during the initial months of the COVID-19 pandemic, the rate of clinical trials that were stopped increased significantly compared with the pre-pandemic era. Of concern, the number of trials 

Ó 2020 by the American College of Cardiology Foundation

cations (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees); has relationships with Clinical Cardiology (deputy editor), the NCDR-ACTION Registry Steering Committee (chair), and the VA CART Research and Publications Committee (chair); has received research funding from Abbott

and Svelte; is a trustee for the American College of Cardiology; and performs unfunded research for FlowCo, Merck, Novo Nordisk, and Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Harvey D. White, DSc, served as Guest Associate Editor for this paper. P.K. Shah, MD, served as Guest Editor-in-Chief for this paper. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines

The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials

Pandemic pandemonium: pausing clinical research during the COVID-19 outbreak

Response of cardiac surgery units to COVID-19: an internationally-based quantitative survey

Association of National Cancer Institute-sponsored clinical trial network group studies with guideline care and new drug indications

Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology Survey